2 days ago
Clinical Advances in Multiple Myeloma From ASCO 2025
The coming of age of chimeric antigen receptor (CAR) T-cell therapy, the selection of postinduction therapy on the basis of residual disease activity, and a novel drug delivery system are among the developments in multiple myeloma (MM) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Dr Joseph Mikhael, from City of Hope Cancer Center in Phoenix, Arizona, opens with long-term follow-up data from the CARTITUDE-1 trial of ciltacabtagene autoleucel CAR T-cell therapy in heavily pretreated relapsed/refractory MM. One third of patients remained progression free for 5 or more years following a single infusion, offering hope of a cure.
Next, he discusses the MIDAS trial of newly diagnosed MM, in which the treatment choice was driven by residual disease activity after induction therapy. The results indicated that autologous stem cell transplant may not be beneficial in patients with no residual disease activity and could potentially be avoided.
Dr Mikhael then turns to follow-up from PERSEUS, again in newly diagnosed disease. The data showed daratumumab to be a key component of both induction therapy when combined with bortezomib, lenalidomide, dexamethasone, and maintenance therapy in combination with lenalidomide.
In closing, he discusses a German trial that underlined the importance of aggressive treatment in high-risk newly diagnosed MM as well as an analysis of an on-body delivery system for subcutaneous isatuximab that met with patient satisfaction.
